Pathological stratification and therapeutic implications for post-stroke depression based on a multidimensional biomarker panel: a narrative review - Takeaways - MDSpire

Pathological stratification and therapeutic implications for post-stroke depression based on a multidimensional biomarker panel: a narrative review

  • By

  • Xinyu Jiang

  • Yujia Fan

  • Yizhi Cui

  • Cui Li

  • Gang Liu

  • June 24, 2026

  • 0 min

Share

  • 1

    Post-stroke depression (PSD) affects approximately 30% of stroke survivors and complicates neurological recovery.

  • 2

    Current treatment guidelines recommend selective serotonin reuptake inhibitors, but many patients do not respond adequately.

  • 3

    PSD is characterized by biological heterogeneity, with potential phenotypes including low-monoamine and high inflammatory burden.

  • 4

    Biomarkers may aid in risk stratification and understanding biological mechanisms, but they are not substitutes for clinical diagnosis.

  • 5

    The review emphasizes the need for future research on biomarker-guided approaches to manage PSD effectively.

Original Source(s)

Pathological stratification and therapeutic implications for post-stroke depression based on a multidimensional biomarker panel: a narrative review

  • by Xinyu Jiang, Yujia Fan, Yizhi Cui, Cui Li, Gang Liu

  • June 24, 2026

Related Content

Psychological distress and caregiver burden among informal caregivers of patients with earthquake-related and stroke-related dependency: a comparative study

A clinically applicable nomogram predicting non-return to work in young and middle-aged patients with acute large vessel occlusion stroke: integrating neurological function and psychosocial factors for personalized rehabilitation

FDA Cites Manufacturing Issues for Cytisinicline

Application supported by Phase 3 smoking-cessation data and long-term safety findings.